Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth Pettengell

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Drugs|September 2, 2009
Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?Ruth Pettengell
British Journal of Haematology|April 3, 2003
Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphomaRuth Pettengell, David Linch,
Drugs of Today (Barcelona, Spain : 1998)|February 4, 2010
Pixantrone maleate for non-Hodgkin's lymphomaDeborah Mukherji, Ruth Pettengell
Expert Opinion on Investigational Drugs|October 18, 2014
MLN8237 ( alisertib ) and its role in peripheral T-cell lymphomaDoraid Alrifai, Ruth Pettengell
Expert Opinion on Pharmacotherapy|June 24, 2010
Pixantrone for the treatment of aggressive non-Hodgkin lymphomaDeborah Mukherji, Ruth Pettengell
Expert Opinion on Biological Therapy|January 9, 2003
PegfilgrastimFenella Willis, Ruth Pettengell
Expert Opinion on Drug Metabolism & Toxicology|September 13, 2011
Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphomaMariam Jamal-Hanjani, Ruth Pettengell
Expert Review of Hematology|February 5, 2013
Pixantrone: merging safety with efficacyDionysios Papadatos-Pastos, Ruth Pettengell
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experienceWilliam Renwick, Ruth Pettengell, Michael Green
FEBS Letters|December 8, 2004
The double life of HOXB4Richard Morgan, Ruth Pettengell, Jastinder Sohal
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Drugs|September 2, 2009
Advanced-stage follicular lymphoma in the rituximab era: when should patients receive anthracycline-based chemotherapy?Ruth Pettengell
British Journal of Haematology|April 3, 2003
Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphomaRuth Pettengell, David Linch,
Drugs of Today (Barcelona, Spain : 1998)|February 4, 2010
Pixantrone maleate for non-Hodgkin's lymphomaDeborah Mukherji, Ruth Pettengell
Expert Opinion on Investigational Drugs|October 18, 2014
MLN8237 ( alisertib ) and its role in peripheral T-cell lymphomaDoraid Alrifai, Ruth Pettengell
Expert Opinion on Pharmacotherapy|June 24, 2010
Pixantrone for the treatment of aggressive non-Hodgkin lymphomaDeborah Mukherji, Ruth Pettengell
Expert Opinion on Biological Therapy|January 9, 2003
PegfilgrastimFenella Willis, Ruth Pettengell
Expert Opinion on Drug Metabolism & Toxicology|September 13, 2011
Pharmacokinetic evaluation of pixantrone for the treatment of non-Hodgkin's lymphomaMariam Jamal-Hanjani, Ruth Pettengell
Expert Review of Hematology|February 5, 2013
Pixantrone: merging safety with efficacyDionysios Papadatos-Pastos, Ruth Pettengell
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|July 25, 2009
Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experienceWilliam Renwick, Ruth Pettengell, Michael Green
FEBS Letters|December 8, 2004
The double life of HOXB4Richard Morgan, Ruth Pettengell, Jastinder Sohal
Pageof 8